



# CLINICAL INSIGHTS

*EXCEL Division of Blue Cross Laboratories*

**LIPONORM Tablet**

**Issue VII, No.20, 2025**

## **Statin Therapy in Early Breast Cancer: The MASTER Trial; A Randomized Phase III, Placebo-Controlled Comparison of Standard (Neo) Adjuvant Therapy Plus Atorvastatin versus Standard (Neo) Adjuvant Therapy Plus Placebo**

*Signe Borgquist, et al. Dig Dis Sci 69, 670–682 (2024). Clin Epidemiol. 2025 Apr 17:17:409-419.*

- Statin use has been consistently associated with improved clinical outcomes (especially recurrence) in breast cancer in multiple observational studies backed by compelling preclinical evidence.
- The biological rationale for cholesterol-lowering statins, as cancer drugs, is evident through actions on several molecular pathways, ie, the mevalonate pathway associated with isoprenoids.
- Double-blind, phase III, randomized, placebo-controlled MASTER (MAMmary cancer STatins in ER positive breast cancer) trial included 1293 women & were administered atorvastatin (80 mg/day) for two years after randomization.
- Atorvastatin was selected given its superior bioavailability, strong affinity to hydroxymethylglutaryl-coenzyme A-reductase (HMGCR), and safety profile even at high dosages with the 80 mg dosing being standard dosing, i.e., as cardio protection following a myocardial infarction due to atherosclerosis.

**Findings from the MASTER trial may ultimately support the integration of Atorvastatin into routine oncologic care, offering a widely available and affordable intervention to improve breast cancer outcomes.**

